TP53 and colorectal carcinoma: As genetic or epigenetic alterations leading to aberrantly expression of antigens, such as TP53 [31] and CTAG1 (also known as NY-ESO-1) [32], may occur in various types of cancer, humoral responses to autoantigens evaluated in our study may also be observed in patients with other malignancies rather than in CRC only.